Market Cap 8.92M
Revenue (ttm) 2.00M
Net Income (ttm) -3.06M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -153.00%
Debt to Equity Ratio 0.00
Volume 43,900
Avg Vol 36,478
Day's Range N/A - N/A
Shares Out 3.21M
Stochastic %K 12%
Beta 1.55
Analysts Strong Buy
Price Target $4.00

Company Profile

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebi...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 327 8778
Address:
245 First Street, Riverview II, 18th Floor, Cambridge, United States
StockTwitsGhost
StockTwitsGhost Jul. 30 at 6:30 AM
$CYCN The gates are open Cyclerion. Make your move! https://www.statnews.com/2025/07/29/vinay-prasad-exits-fda-marty-makary-cber-director-chief-medical-scientific-officer/
0 · Reply
StockTwitsGhost
StockTwitsGhost Jul. 30 at 6:27 AM
$CYCN Almost 5 months since the March deck and it’s beginning to look more and more like a Harris Walz meme. Cyclerion it’s time to be unburdened by what has been.
0 · Reply
StockTwitsGhost
StockTwitsGhost Jul. 30 at 6:17 AM
$CYCN This evening's FDA announcement presents a golden opportunity for Cyclerion to strategically release positive developments. A primary critique of CYCN is their apparent reluctance or inability to effectively engage with all shareholders and, more crucially, to sell themselves to Wall Street and all investors. Whoever approved their current communication strategy has miscalculated—it’s clearly ineffective. The leadership’s failure to grasp the importance of strategic marketing and persuasive communication is evident. The stock price, languishing at $2.73 per share, speaks volumes. Dismiss my perspective if you will, but the numbers don’t lie. Furthermore, the much-touted hiring of an investor relations professional is a hollow gesture unless paired with action. What drives momentum is a compelling narrative of hope, ambition, and a clear vision for the future. Cyclerion must break free from its past constraints and act decisively—now is the time for a transformative announcement.
0 · Reply
AshleySchaeffer_BMW
AshleySchaeffer_BMW Jul. 30 at 12:33 AM
$CYCN keep shorting shorts, would be nice to pick up another 10k shares before news
1 · Reply
BiotechValues
BiotechValues Jul. 29 at 7:48 PM
$CYCN - FWIW, $GLMD has a board that literally is almost a carbon copy of here. Everyone talking about an in-license (obesity asset), waiting for news, conspiracy theories, etc.
2 · Reply
Jmoney914
Jmoney914 Jul. 29 at 7:19 PM
$CYCN trying to carve out the rest of my position down here! Gotta love it when you can avg down in a stock because you want to!
0 · Reply
skyrockets_Inc
skyrockets_Inc Jul. 29 at 7:01 PM
$CYCN Anyone else find this stock movement the last week oddly familiar? Looks eerily similar to the last two times it ripped. Could we be ready for round 3?
1 · Reply
skyrockets_Inc
skyrockets_Inc Jul. 29 at 6:40 PM
$CYCN Back to the good ole days of CYCN w/ $0.36 bid/ask spreads
0 · Reply
SDBiotechInvestor
SDBiotechInvestor Jul. 29 at 4:12 PM
$CYCN - hopefully down to the last week or so.
1 · Reply
skyrockets_Inc
skyrockets_Inc Jul. 29 at 3:18 PM
$CYCN less than ~2 weeks until 10q and hopefully a concurrent PR. This time last year they released PR w/ 10q on Aug 7.
1 · Reply
Latest News on CYCN
Regina Graul, Ph.D., Promoted to Chief Executive Officer

Aug 7, 2024, 7:00 AM EDT - 1 year ago

Regina Graul, Ph.D., Promoted to Chief Executive Officer


Cyclerion Appoints Regina Graul, Ph.D., as President

Dec 4, 2023, 8:00 AM EST - 1 year ago

Cyclerion Appoints Regina Graul, Ph.D., as President


Cyclerion Announces Reverse Stock Split

May 15, 2023, 1:00 PM EDT - 2 years ago

Cyclerion Announces Reverse Stock Split


Cyclerion Therapeutics to Host Pipeline Update Webinar

Apr 20, 2021, 7:00 AM EDT - 4 years ago

Cyclerion Therapeutics to Host Pipeline Update Webinar


StockTwitsGhost
StockTwitsGhost Jul. 30 at 6:30 AM
$CYCN The gates are open Cyclerion. Make your move! https://www.statnews.com/2025/07/29/vinay-prasad-exits-fda-marty-makary-cber-director-chief-medical-scientific-officer/
0 · Reply
StockTwitsGhost
StockTwitsGhost Jul. 30 at 6:27 AM
$CYCN Almost 5 months since the March deck and it’s beginning to look more and more like a Harris Walz meme. Cyclerion it’s time to be unburdened by what has been.
0 · Reply
StockTwitsGhost
StockTwitsGhost Jul. 30 at 6:17 AM
$CYCN This evening's FDA announcement presents a golden opportunity for Cyclerion to strategically release positive developments. A primary critique of CYCN is their apparent reluctance or inability to effectively engage with all shareholders and, more crucially, to sell themselves to Wall Street and all investors. Whoever approved their current communication strategy has miscalculated—it’s clearly ineffective. The leadership’s failure to grasp the importance of strategic marketing and persuasive communication is evident. The stock price, languishing at $2.73 per share, speaks volumes. Dismiss my perspective if you will, but the numbers don’t lie. Furthermore, the much-touted hiring of an investor relations professional is a hollow gesture unless paired with action. What drives momentum is a compelling narrative of hope, ambition, and a clear vision for the future. Cyclerion must break free from its past constraints and act decisively—now is the time for a transformative announcement.
0 · Reply
AshleySchaeffer_BMW
AshleySchaeffer_BMW Jul. 30 at 12:33 AM
$CYCN keep shorting shorts, would be nice to pick up another 10k shares before news
1 · Reply
BiotechValues
BiotechValues Jul. 29 at 7:48 PM
$CYCN - FWIW, $GLMD has a board that literally is almost a carbon copy of here. Everyone talking about an in-license (obesity asset), waiting for news, conspiracy theories, etc.
2 · Reply
Jmoney914
Jmoney914 Jul. 29 at 7:19 PM
$CYCN trying to carve out the rest of my position down here! Gotta love it when you can avg down in a stock because you want to!
0 · Reply
skyrockets_Inc
skyrockets_Inc Jul. 29 at 7:01 PM
$CYCN Anyone else find this stock movement the last week oddly familiar? Looks eerily similar to the last two times it ripped. Could we be ready for round 3?
1 · Reply
skyrockets_Inc
skyrockets_Inc Jul. 29 at 6:40 PM
$CYCN Back to the good ole days of CYCN w/ $0.36 bid/ask spreads
0 · Reply
SDBiotechInvestor
SDBiotechInvestor Jul. 29 at 4:12 PM
$CYCN - hopefully down to the last week or so.
1 · Reply
skyrockets_Inc
skyrockets_Inc Jul. 29 at 3:18 PM
$CYCN less than ~2 weeks until 10q and hopefully a concurrent PR. This time last year they released PR w/ 10q on Aug 7.
1 · Reply
AshleySchaeffer_BMW
AshleySchaeffer_BMW Jul. 29 at 3:11 PM
$CYCN added another 2k shares today, thanks for the cheapies shorty
0 · Reply
skyrockets_Inc
skyrockets_Inc Jul. 28 at 8:32 PM
$CYCN One of the founders and CSO of CVCO Therapeutics, Mark Currie, is also a Venture Partner at Iaso Ventures. This also could be another way that CVCO plans to get funded in order to license Olinciguat from us. News on this license deal is due by Aug 18 at the latest. Interestingly enough, Iaso Ventures also has funded Beacon Biosignals...which some in here have speculated that we may be partnering with for the TRD device. Lots of connections!
1 · Reply
EZYME22
EZYME22 Jul. 28 at 6:30 PM
$CYCN anyone know why yahoo finance is showing 3.55 shares outstanding? lates cycn filings is 3.2M
1 · Reply
skyrockets_Inc
skyrockets_Inc Jul. 28 at 2:38 PM
$CYCN IR has been increasingly more responsive which is a good sign. If bad things were to come they would just stayed silent like they have for the past entire year. Nothing of substance here but email chance below....at least he's responsive. " Thanks, Neil. Is there any general timeline you can share with us? Do you think a PR will be disclosed before the end of Q3? I know the CVCO Olinciguat out-license deadline should be sometime coming up in mid-late August. Looking forward to hearing updates soon." Response: "unfortunately we cannot provide any timelines, but we will provide disclosures as they come. Hope you have a great weekend, Neil"
1 · Reply
skyrockets_Inc
skyrockets_Inc Jul. 28 at 2:36 PM
$CYCN 2.70 hard support. Insiders also bought at this level. Buying more here.
0 · Reply
Mr_Pithy
Mr_Pithy Jul. 28 at 2:18 PM
0 · Reply
StockTwitsGhost
StockTwitsGhost Jul. 28 at 8:24 AM
$CYCN If not now, then when Today
2 · Reply
StockTwitsGhost
StockTwitsGhost Jul. 28 at 5:29 AM
$CYCN Beacon Biosignals is the top fit for Cyclerion’s TRD program, surpassing Pascall Systems with its AI-driven EEG analytics, prior Cyclerion partnership, and precision medicine alignment (85% partnership probability vs. Pascall’s 80%; 70% acquisition vs. 65%). Ceribell, Inc. is a strong second with its FDA-cleared, AI-enhanced EEG system, ideal for neurodiagnostics, but lacks TRD-specific data (78% partnership, 60% acquisition). Cognito Therapeutics’ gamma-frequency neuromodulation and NeuroPace’s FDA-approved RNS System are less suitable due to their Alzheimer’s focus and invasive approach, respectively (75% and 70% partnership; 60% and 55% acquisition). Cyclerion should prioritize a deepened partnership with Beacon to leverage its EEG platform for TRD biofeedback, with Ceribell as a hardware fallback. Acquisition is less feasible due to Cyclerion’s financial constraints and high valuations of these firms.
0 · Reply
StockTwitsGhost
StockTwitsGhost Jul. 28 at 5:05 AM
$CYCN Larry 🦜 stated the following: Pascall Systems, Inc. is a strong potential fit for Cyclerion Therapeutics due to its FDA 510(k)-cleared wireless EEG system, which aligns with Cyclerion’s need for a biofeedback-driven device to treat TRD by resetting brainwave patterns. The system’s Phase 3 trial readiness and non-invasive design further enhance its appeal, supporting Cyclerion’s goal of developing a safer, patient-friendly alternative to ECT. Cyclerion’s history of EEG-focused partnerships and strategic focus on personalized medicine bolster the case for collaboration or acquisition. Probability Assessment: Overall Fit: 72.5% likelihood that Pascall is a good fit for Cyclerion’s TRD program. Partnership: 80% likelihood, as it aligns with Cyclerion’s collaborative approach and minimizes financial risk. Acquisition: 65% likelihood, contingent on Pascall’s valuation, technological uniqueness, and Cyclerion’s financial capacity.
0 · Reply
EZYME22
EZYME22 Jul. 27 at 12:06 PM
$CYCN https://www.pascallsystems.com i think this is the company we will license from
2 · Reply
SDBiotechInvestor
SDBiotechInvestor Jul. 26 at 5:20 PM
$CYCN - Happy Saturday fam
0 · Reply
gourmetmacncheese
gourmetmacncheese Jul. 25 at 8:15 PM
$CYCN Family dysfunction
0 · Reply